Safety and clinical effect of subcutaneous human interleukin-21 in patients with metastatic melanoma or renal cell carcinoma: a phase I trial

Research output: Contribution to journal › Journal article › Research › peer-review

  • Henrik Schmidt
  • Janet Brown
  • Ulrik Mouritzen
  • Peter Selby
  • Kirsten Fode
  • Svane, Inge Marie
  • Graham P Cook
  • David Hal Mollerup
  • Poul F Geertsen
This phase I study in patients with metastatic melanoma (MM) and renal cell carcinoma (RCC) evaluated the safety and maximum tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of s.c. treatment of human recombinant interleukin 21 (IL-21).
Original languageEnglish
JournalClinical Cancer Research
Volume16
Issue number21
Pages (from-to)5312-9
Number of pages8
ISSN1078-0432
DOIs
Publication statusPublished - 1 Nov 2010

ID: 34133708